Featured Publications
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2023
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.Peer-Reviewed Original ResearchTreatment of physician's choiceIndividual patient dataOral SERDsMetastatic breast cancerPFS benefitKaplan MeierBreast cancerEstimate time-to-event outcomesHER2- metastatic breast cancerESR1 mutation statusIndividual patient data meta-analysisOverall populationAdvanced breast cancerMeta-analysisMutant subgroupESR1 mutationsEndocrine therapyMutation statusRandomised controlled trialsOverall cohortPooled analysisDrug classesPFSPhysician's choicePreferred Reporting Items
2022
UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies
Tan D, Lim W, Yong J, Ng C, Muthiah M, Tan E, Xiao J, Lim S, Pin Tang A, Pan X, Kabir T, Bonney G, Sundar R, Syn N, Kim B, Dan Y, Noureddin M, Loomba R, Huang D. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical Gastroenterology And Hepatology 2022, 21: 1475-1484. PMID: 35181565, DOI: 10.1016/j.cgh.2022.02.018.Peer-Reviewed Original ResearchConceptsUNOS-DS criteriaHepatocellular carcinoma recurrenceUNOS-DSDown-stagingOverall survivalLiver transplantationHepatocellular carcinomaMilan criteriaPost-LTLiver transplantation of hepatocellular carcinomaTransplantation of hepatocellular carcinomaAbstractText Label="RESULTS">WeAdult HCC patientsBaseline tumor burdenPost-LT outcomesDown-staging treatmentTumor burdenHCC patientsEmbase databasesPooled analysisPatientsIndividual participant dataRecurrenceClinical validationMeta-analysis